Radiopharm Theranostics (ASX: RAD) has announced that patient enrollment has commenced for the third cohort of its ongoing Phase 1 dose-escalation trial evaluating 177Lu-RAD204, a radiolabeled single-domain antibody targeting PD-L1 in advanced solid tumours. …
Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 in PD-L1 positive cancers
November 12, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News